- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02107846
An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112
September 27, 2016 updated by: Protalix
A Phase 2a, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (Plant Recombinant Human Glucocerebrosidase) in Enzyme Replacement Therapy-Naïve Subjects With Gaucher Disease
This is an open-label, dose escalation study to evaluate the safety of oral PRX-112 and pharmacokinetics of GCD in subjects with Gaucher disease naive to enzyme replacement therapy.
The dose levels of PRX-112 are 50 units, 100 units, 200 units and 400 units GCD.
Subjects will receive once daily oral administrations of PRX-112 for 5 consecutive days at each dose level with a 2-day washout period between doses.
Study Overview
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jerusalem, Israel
- Shaare Zedek Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female age 18 or older
- Historical diagnosis of Gaucher disease by low leukocyte GCD activity level
- Haemoglobin ≥ 10 g/dL
- Body mass index (BMI) of 18 kg/m2-30 kg/m2 inclusive
- Subject is able to provide written informed consent
- Female subjects of child bearing potential must not be pregnant or lactating with a negative urine pregnancy test result at the screening visit.
- Female subjects of child-bearing potential and male subjects with female partners of childbearing potential must use two methods of contraception at all times during the study, one of which must be a barrier method. Acceptable methods of contraception are oral contraceptives, barrier methods (male condom, female condom, diaphragm, cervical cap, spermicide or intrauterine device), surgical sterility (documented doctor's report of vasectomy, hysterectomy and/or bilateral oophorectomy) and/or postmenopausal status (defined as at least 1 year without menses as demonstrated by medical history or subject report).
- Negative laboratory tests for HIV, HBsAg and HCV at the screening visit
- Naïve to any previous ERT or have received the last ERT treatment 12 months before signing IC
Exclusion Criteria:
- Presence of a gastrointestinal (GI) disease affecting motility or absorption
- Subjects with any history of allergic response to biological drugs or other allergies deemed clinically significant by the Investigator
- Reported history of alcohol or drug abuse
- Subject has donated blood in the 3 months prior to screening or subject has received plasma derivatives in the 6 months prior to screening
- Use of any investigational drug or participation in another clinical trial in the 3 months prior to screening (subject report)
- Subjects who have previously received ERT with positive anti-human plant recombinant GCD (prGCD) antibodies
- Clinical evidence of any active significant disease that could potentially compromise the ability of the Investigator to evaluate or interpret the effects of the study treatment on safety assessment, thus increasing the risk to the subject to unacceptable levels
- Presence of any medical, emotional, behavioural or psychological condition that, in the judgement of the Investigator, would interfere the compliance requirements of the study
- Subject has used any medication (excluding acetaminophen or dyprione) within 7 days of screening, including laxatives, teas and food additives known to be used for the treatment of constipation or diarrhea
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 50 Units
PRX-112 50 Units daily for 5 days
|
Other Names:
|
Experimental: 100 Units
PRX-112 100 Units daily for 5 days
|
Other Names:
|
Experimental: 200 Units
PRX-112 200 Units daily for 5 days
|
Other Names:
|
Experimental: 400 Units
PRX-112 400 Units daily for 5 days
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the curve
Time Frame: 24 hours
|
Blood samples for GCD level every 2 hours for 24 hours
|
24 hours
|
Adverse Events
Time Frame: 7 Days
|
Reporting of adverse events collected daily
|
7 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
April 4, 2014
First Submitted That Met QC Criteria
April 4, 2014
First Posted (Estimate)
April 8, 2014
Study Record Updates
Last Update Posted (Estimate)
September 28, 2016
Last Update Submitted That Met QC Criteria
September 27, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Gaucher Disease
Other Study ID Numbers
- PB-112-02a
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gaucher Disease
-
KemPharm Denmark A/STerminatedGaucher Disease, Type 1 | Gaucher Disease, Type 3India
-
AVROBIOWithdrawn
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, United States
-
Genzyme, a Sanofi CompanyActive, not recruitingGaucher Disease Type 1 | Gaucher Disease Type 3Germany, United States, Japan, United Kingdom
-
Baylor Research InstituteTexas Scottish Rite Hospital for ChildrenWithdrawnGaucher Disease Type 1 | Gaucher Disease Type 3United States
-
CANbridge (Suzhou) Bio-pharma Co., Ltd.RecruitingGaucher Disease, Type 1 | Gaucher Disease, Type 3China
-
Cambridge University Hospitals NHS Foundation TrustMedical Research Council; National Institute for Health Research, United KingdomRecruitingGaucher Disease, Type III | Gaucher Disease, Type IUnited Kingdom
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited States
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, Israel, South Africa, United States
-
Freeline TherapeuticsRecruitingGaucher Disease, Type 1Spain, Israel, United States, United Kingdom, Brazil, Germany, Paraguay
Clinical Trials on PRX-112
-
ProtalixCompleted
-
Ology BioservicesCompletedPost Traumatic Stress DisorderUnited States
-
Epix Pharmaceuticals, Inc.TerminatedPulmonary Hypertension | COPDUnited States
-
Promontory Therapeutics Inc.Active, not recruitingUrogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Advanced Solid Tumors | mCRPC | Metastatic Castrate-resistant Prostate Cancer | CRPC | PT-112United States, France
-
Epix Pharmaceuticals, Inc.CompletedChronic Obstructive Pulmonary Disease | Pulmonary HypertensionUnited States
-
Chiesi Farmaceutici S.p.A.Active, not recruitingFabry DiseaseUnited States, Netherlands, Australia, Hungary, United Kingdom, Canada, Czechia, Finland, France, Italy, Norway, Slovenia, Spain
-
Chiesi Farmaceutici S.p.A.Active, not recruitingFabry DiseaseBelgium, United States, United Kingdom, Italy, Czechia, Denmark, Norway
-
ProtalixRecruiting
-
Promontory Therapeutics Inc.CompletedMultiple MyelomaUnited States
-
National Cancer Institute (NCI)RecruitingThymic Epithelial Tumor | Thymic Cancer | Recurrent ThymomaUnited States